Insights

Strategic partnerships Collaborate with Lilly and other pharma players via co-development or supply agreements to access broader oncology targets and combination therapy opportunities, leveraging Prelude’s precision oncology pipeline.

Clinical expansion Leverage ongoing Phase 1 collaboration with abemaciclib and imlunestrant to explore additional CDK4/6 inhibitor or ER pathway combinations, expanding into HR+/HER2− breast cancer and potentially other hormone-responsive cancers.

KAT6A leadership Capitalize on first-in-class PRT13722 KAT6A degrader capability to position as a backbone for collaboration deals with CROs, biotech partners, and academic groups for joint preclinical and translational programs.

Degrader DACs Position targeted protein degradation platform and next-generation DACs with novel payloads as high-value licensing or co-development targets for early-stage biotechs seeking novel oncology modalities.

Financial leverage Highlight substantial funding and recurring revenue potential to attract strategic acquirers or partners, emphasizing scalable clinical programs and infrastructure supported by a $297M funding runway.

Similar companies to Prelude Therapeutics

Prelude Therapeutics Tech Stack

Prelude Therapeutics uses 8 technology products and services including Qlik, Amazon Web Services, Drupal, and more. Explore Prelude Therapeutics's tech stack below.

Media & News

Prelude Therapeutics's Email Address Formats

Prelude Therapeutics uses at least 4 email formats:
Prelude Therapeutics Email FormatsExamplePercentage
FLast@preludetx.comJDoe@preludetx.com
93%
Last@preludetx.comDoe@preludetx.com
5%
FL@preludetx.comJD@preludetx.com
1%
Middle@preludetx.comMichael@preludetx.com
1%

Frequently Asked Questions

What is Prelude Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Prelude Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Prelude Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Prelude Therapeutics is a publicly traded company; the company's stock symbol is PRLD.

What is Prelude Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Prelude Therapeutics's official website is preludetx.com and has social profiles on LinkedIn.

How much revenue does Prelude Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Prelude Therapeutics's annual revenue is estimated to be $10M - $25M.

What is Prelude Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Prelude Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Prelude Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Prelude Therapeutics has approximately 101 employees across 2 continents, including North America and Europe. Key team members include Chief Financial Officer, Chief Legal Officer And Secretary: B. L., Executive Director: S. R. and Director, Development Operations: J. T. Explore Prelude Therapeutics's employee directory with LeadIQ.

What industry does Prelude Therapeutics belong to?

Minus sign iconPlus sign icon
Prelude Therapeutics operates in the Biotechnology Research industry.

What technology does Prelude Therapeutics use?

Minus sign iconPlus sign icon
Prelude Therapeutics's tech stack includes Qlik, Amazon Web Services, Drupal, WordPress, Shopify, OpenAI, WP Engine and Paylocity.

What is Prelude Therapeutics's email format?

Minus sign iconPlus sign icon
Prelude Therapeutics's email format typically follows the pattern of FLast@preludetx.com. Find more Prelude Therapeutics email formats with LeadIQ.

How much funding has Prelude Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Prelude Therapeutics has raised $297M in funding. The last funding round occurred on Apr 21, 2026.

When was Prelude Therapeutics founded?

Minus sign iconPlus sign icon
Prelude Therapeutics was founded in 2016.
Prelude Therapeutics logo

Prelude Therapeutics

Biotechnology ResearchDelaware, United States51-200 Employees

Prelude Therapeutics is a biotechnology research company focused on precision oncology. Based in Wilmington, Delaware, it develops medicines aimed at cancer patients with high unmet medical needs. The company pursues targeted protein degradation approaches targeting clinically validated cancer mechanisms, with additional modalities under exploration.

The organization serves researchers, clinicians, and potential pharmaceutical partners seeking novel cancer therapies grounded in precision medicine. Public reporting has described Prelude as a clinical-stage precision oncology company, and in 2026 it presented preclinical data on a development candidate at the AACR meeting, signaling ongoing advancement.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
PRLD
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $297M

    Prelude Therapeutics has raised a total of $297M of funding over 6 rounds. Their latest funding round was raised on Apr 21, 2026 as a Post IPO Equity.

  • $10M - $25M

    Prelude Therapeutics's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.